Endothelin receptor antagonist prevents parathyroid cell proliferation of low calcium diet-induced hyperparathyroidism in rats.

Secondary hyperparathyroidism, one of the most frequently encountered disorders of the calcium homeostasis, is characterized by an increase in parathyroid epithelial (PT) cell number, which is crucial from a functional viewpoint. However, it is still unknown what factors are involved in PT cell proliferation. Endothelin-1 (ET-1), a vasoconstrictive peptide, has been shown to act as a mitogen in a variety of cell types. Rat PT cells are reported to synthesize ET-1 and possess its receptors. To test the hypothesis that ET-1 plays a role in PT cell proliferation, we used rat test subjects fed a low calcium diet for 8 weeks (low Ca rats). The number of the proliferating PT cells, measured by proliferating cell nuclear antigen immunostaining, was significantly increased, with striking immunoreactivity of ET-1 in the low Ca rats. An endothelin receptor antagonist, bosentan (100 mg/kg.day), prevented any increase in the proliferation of PT cells in the low Ca rats (14.3 +/- 2.7/1000 PT cells with no bosentan; 2.1 +/- 1.3 with bosentan; P < 0.01). These results indicate that ET-1 is involved in PT cell proliferation in vivo and suggest that blocking of ET receptors may become one of the important therapeutic strategies for preventing secondary hyperparathyroidism.

[1]  汪关煜 Renal osteodystrophy , 2002 .

[2]  J. Silver,et al.  Regulation of parathyroid cell proliferation , 1997, Current opinion in nephrology and hypertension.

[3]  G. Mazzocchi,et al.  Endothelins stimulate deoxyribonucleic acid synthesis and cell proliferation in rat adrenal zona glomerulosa, acting through an endothelin A receptor coupled with protein kinase C- and tyrosine kinase-dependent signaling pathways. , 1997, Endocrinology.

[4]  A. Parfitt,et al.  The basal rate of cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism , 1997, Clinical endocrinology.

[5]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[6]  Z. Pausova,et al.  Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. , 1996, The Journal of clinical endocrinology and metabolism.

[7]  A. Arnold,et al.  Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. , 1996, The Journal of clinical endocrinology and metabolism.

[8]  A. Ullrich,et al.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.

[9]  S. Oparil,et al.  ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. , 1995, The American journal of physiology.

[10]  J. Silver,et al.  Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. , 1995, The Journal of clinical investigation.

[11]  E. Brown,et al.  Loss of calcium responsiveness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. , 1995, Biochemical and biophysical research communications.

[12]  F. Brunner,et al.  Dependence of endothelin-1 secretion on Ca2+. , 1995, Biochemical pharmacology.

[13]  M. Brandi,et al.  Effects of endothelin‐1 on Ca2+ signaling and secretion in parathyroid cells , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  C. Peiró,et al.  Influence of endothelium on cultured vascular smooth muscle cell proliferation. , 1995, Hypertension.

[15]  B. Löffler,et al.  Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). , 1994, Circulation.

[16]  M. Polokoff,et al.  Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. , 1994, Pharmacological reviews.

[17]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[18]  W. Neidhart,et al.  Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist , 1993, Nature.

[19]  W. G. Haynes,et al.  Endothelins as regulators of growth and function in endocrine tissues , 1993, Clinical endocrinology.

[20]  G. Remuzzi,et al.  A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. , 1993, Kidney international.

[21]  F. Marumo,et al.  Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. , 1992, Biochemical pharmacology.

[22]  L. Opie,et al.  Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. , 1992, Journal of molecular and cellular cardiology.

[23]  J. Pouysségur,et al.  Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells. , 1992, The Biochemical journal.

[24]  M. Yanagisawa,et al.  Endothelin receptors in human parathyroid gland. , 1992, Biochemical and biophysical research communications.

[25]  T. Horio,et al.  Release mechanism of endothelin-1 and big endothelin-1 after stimulation with thrombin in cultured porcine endothelial cells. , 1992, Journal of vascular research.

[26]  M. Shichiri,et al.  Cellular Mechanism of Endothelin‐1 Release by Angiotensin and Vasopressin , 1991, Hypertension.

[27]  M. Brandi,et al.  Endothelin as an autocrine factor in the regulation of parathyroid cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Shichiri,et al.  Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. , 1991, The Journal of clinical investigation.

[29]  E. Schiffrin,et al.  Plasma endothelin in human essential hypertension. , 1991, American journal of hypertension.

[30]  J. Silver,et al.  Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. , 1990, The Journal of clinical investigation.

[31]  G. Hendy,et al.  Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. , 1989, Endocrinology.

[32]  P. Bouloux,et al.  Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. , 1989, The New England journal of medicine.

[33]  J. Burnett,et al.  Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. , 1989, European journal of pharmacology.

[34]  M. Yanagisawa,et al.  A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. , 1989, The Journal of biological chemistry.

[35]  G. Dubyak,et al.  Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. , 1989, The Journal of clinical investigation.

[36]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[37]  M. Brandi,et al.  Functional epithelial cell line cloned from rat parathyroid glands. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Tan,et al.  Autoantibody to a nuclear antigen in proliferating cells. , 1978, Journal of immunology.

[39]  C. Itakura,et al.  Renal Secondary Hyperparathyroidism in Aged Sprague-Dawley Rats , 1977, Veterinary pathology.

[40]  E. Brown,et al.  The extracellular calcium-sensing receptor: its role in health and disease. , 1998, Annual review of medicine.

[41]  Lai Yh,et al.  Interaction between extracellular calcium and endothelin-1 influences parathyroid hormone secretion from bovine parathyroid cells through the increase in intracellular calcium. , 1997 .

[42]  J. Vane,et al.  The Fate of Radioiodinated Endothelin‐1 and Endothelin‐3 in the Rat , 1989, Journal of cardiovascular pharmacology.